373 related articles for article (PubMed ID: 28439702)
1. A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.
Mayer A; Schuster P; Fink B
Arch Orthop Trauma Surg; 2017 Jun; 137(6):797-803. PubMed ID: 28439702
[TBL] [Abstract][Full Text] [Related]
2. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Squizzato A; Lussana F; Cattaneo M
Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Messerschmidt C; Friedman RJ
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):771-8. PubMed ID: 25767271
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Direct Oral Anticoagulant Treatment for Acute Lower Limb Deep Venous Thrombosis After Total Knee Arthroplasty Or Total Hip Arthroplasty.
Mochizuki T; Ikari K; Yano K; Hiroshima R; Ishibashi M; Okazaki K
Mod Rheumatol; 2019 Jul; 29(4):682-686. PubMed ID: 30041559
[No Abstract] [Full Text] [Related]
5. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
[TBL] [Abstract][Full Text] [Related]
6. Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
Samama CM; Rosencher N; Kleine E; Feuring M; Brueckmann M; Clemens A; Gullberg J; Frostick SP
Thromb Res; 2016 Jul; 143():103-10. PubMed ID: 27208980
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Burness CB; McKeage K
Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
[TBL] [Abstract][Full Text] [Related]
8. Implications of new anticoagulants in primary practice.
Perez A; Eraso LH; Merli GJ
Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran vs. low molecular weight heparin in preventing venous thromboembolism after elective hip and knee arthroplasty: evaluation of selected clinical parameters.
Mrozik D; Jackiewicz A; Krzemiński M
Pol Orthop Traumatol; 2012 Oct; 77():111-4. PubMed ID: 23306297
[TBL] [Abstract][Full Text] [Related]
10. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
Highcock AJ; As-Sultany M; Finley R; Donnachie NJ
J Arthroplasty; 2020 Nov; 35(11):3093-3098. PubMed ID: 32674939
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
[TBL] [Abstract][Full Text] [Related]
14. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
16. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
17. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Alves C; Batel-Marques F; Macedo AF
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):266-76. PubMed ID: 22134134
[TBL] [Abstract][Full Text] [Related]
18. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
19. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Cohen A; Drost P; Marchant N; Mitchell S; Orme M; Rublee D; Simon TA; Sutton A
Clin Appl Thromb Hemost; 2012 Nov; 18(6):611-27. PubMed ID: 22387582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
